Sanofi, FDA and Dupixent
Sanofi blockbuster drug wins clearance in US for lung disease
Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after a similar decision by European regulators.
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said on Friday.
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD
Dupixent, commonly used to treat eczema and asthma, was cleared for a subset of patients with chronic obstructive pulmonary disease.
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
Sanofi recorded 10.72 billion euros ($11.94 billion) in sales for Dupixent in 2023, which includes Regeneron's share. Analysts on average expect Dupixent, by far Sanofi's best-selling drug, to generate more than 21 billion euros in sales in 2030,
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
Regeneron stock XX on XX after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.
Sanofi CEO believes company poised for growth from new drugs
Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a ...
STAT2d
The science behind Summit’s success, 23andMe’s fate, and more biotech news updates
Amgen's immunology drug results —The Novo Nordisk Senate hearing —Sanofi's soul-searching Read on to learn more.
FiercePharma2d
Private equity firms bid on Sanofi's $16B+ consumer health business: Bloomberg
As private equity firms reportedly place their bids, Sanofi may soon follow in the footsteps of GSK and Johnson & Johnson ...
Sanofi CEO still considering how to split consumer biz, hopes to keep a stake
Sanofi Chief Executive Paul Hudson said on Monday that the company has not made a final decision yet on how it plans to split ...
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately ...
devdiscourse3d
Top Health News: Drug Trials, Bird Flu, and Mpox Updates
This summary covers various health news briefs including AstraZeneca's breast cancer drug trial results, a bird flu case in ...
Sanofi gets two bids valuing its consumer health unit at about $17 billion, Bloomberg News reports
Sanofi has received two separate bids for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion ...
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) ...
Yahoo Finance16d
Sanofi inaugurates vaccine plant in Neuville-sur-Saône, France
It will create 200 jobs in France. Sanofi CEO Paul Hudson stated: “The creation of Modulus is one of our greatest ...
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...
The Bakersfield Californian9h
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients ...
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype ...